| 严国建,何昌九,胡萱怡,蒲 丽,宋旭峰,纪 伟,雷家铃,杨 俊.氟西汀联合利培酮对精神分裂症患者血脂代谢、认知中记忆维度和血清神经营养因子的影响[J].现代生物医学进展英文版,2021,(16):3151-3154. |
| 氟西汀联合利培酮对精神分裂症患者血脂代谢、认知中记忆维度和血清神经营养因子的影响 |
| Effects of Fluoxetine Combined with Risperidone on Blood Lipid Metabolism, Cognitive Memory Dimension and Serum Neurotrophic Factor in Patients with Schizophrenia |
| Received:February 04, 2021 Revised:February 26, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.16.031 |
| 中文关键词: 氟西汀 利培酮 精神分裂症 血脂代谢 认知中记忆维度 神经营养因子 |
| 英文关键词: Fluoxetine Risperidone Schizophrenia Lipid metabolism Cognitive memory dimension Neurotrophic factor |
| 基金项目:四川省2017年卫生健康委员会科研项目（17PJ087） |
|
| Hits: 697 |
| Download times: 387 |
| 中文摘要: |
| 摘要 目的：探讨氟西汀联合利培酮对精神分裂症患者血脂代谢、认知中记忆维度和血清神经营养因子的影响。方法：本次研究纳入病例110例，选取自2018年3月~2020年8月期间我院接收的精神分裂症患者。根据就诊奇偶顺序将患者分为对照组和研究组，各55例。对照组给予利培酮治疗，研究组给予氟西汀联合利培酮治疗，均治疗12周。对比两组治疗12周后的疗效，对比两组治疗前、治疗12周后的血脂代谢、认知中记忆维度、血清神经营养因子水平及阳性和阴性症状量表（PANSS）评分，记录两组不良反应发生率。结果：研究组的临床总有效率优于对照组（P<0.05）。两组治疗12周后总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）较治疗前升高，高密度脂蛋白（HDL-C）降低较治疗前（P<0.05）。两组治疗12周后简易视觉空间记忆测验-修订版（BVMT-R）、韦克斯勒空间广度测验-Ⅲ（WMS-Ⅲ）、霍普金斯词语学习测验-修订版（HVLT-R）评分升高，且研究组高于对照组（P<0.05）。两组治疗12周后血清脑源性神经营养因子（BDNF）、胶质源性神经营养因子（GDNF）升高，且研究组高于对照组（P<0.05）。两组治疗12周后阳性症状评分、一般病理评分、总分、阴性症状评分降低，且研究组较对照组低（P<0.05）。两组不良反应总发生率比较无差异（P>0.05）。结论：氟西汀联合利培酮治疗精神分裂症患者，可有效改善认知功能，改善血清神经营养因子水平，且不加重血脂紊乱程度，不增加不良反应发生率，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of fluoxetine combined with risperidone on blood lipid metabolism, cognitive memory dimension and serum neurotrophic factor in patients with schizophrenia. Methods: 110 schizophrenic patients from March 2018 to August 2020 were included in this study. According to the parity order, the patients were divided into control group and study group, 55 cases in each group. The control group was treated with risperidone, and the study group was treated with fluoxetine combined with risperidone for 12 weeks. The efficacy of the two groups 12 weeks after treatment was compared. The blood lipid metabolism, cognitive memory dimension, serum neurotrophic factor level and positive and negative symptom scale (PANSS) scores of the two groups before and 12 weeks after treatment were compared. The incidence of adverse reactions of the two groups was recorded. Results: The total effective rate of the study group was better than that of the control group (P<0.05). The total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL-C) of the two groups were increased 12 weeks after treatment, while the high density lipoprotein (HDL-C) was decreased 12 weeks after treatment(P<0.05).12 weeks after treatment, the scores of Simplified visual spatial memory test revised (BVMT-R), Wechsler spatial span test-Ⅲ (WMS-Ⅲ), Hopkins Word Learning Test revised (HVLT-R) in the study group were higher than those in the control group (P<0.05). 12 weeks after treatment, the serum levels of brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF) increased in the two groups, and the levels in the study group were higher than those in the control group(P<0.05). 12 weeks after treatment, the positive symptom score, general pathology score, total score, negative symptom score of the two groups decreased, and the study group was lower than the control group (P<0.05). There was no difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Fluoxetine Combined with risperidone in the treatment of schizophrenia can effectively improve cognitive function, improve serum neurotrophic factor levels, and does not aggravate the degree of dyslipidemia, does not increase the incidence of adverse reactions, safe and effective. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
